Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
In cancer chemotherapy neutropenia is a common dose-limiting toxicity. An ability to predict the neutropenic effects of cytotoxic agents based on proposed trial designs and models conditioned on previous studies would be valuable. The aim of this study was to evaluate the ability of a semi-mechanist...
Main Authors: | Soto, Elena, Keizer, Ron J., Trocóniz, Iñaki F., Huitema, Alwin D. R., Beijnen, Jos H., Schellens, Jan H. M., Wanders, Jantien, Cendrós, Josep María, Obach, Rosendo, Peraire, Concepción, Friberg, Lena E., Karlsson, Mats O. |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer US
2010
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160557/ |
Similar Items
-
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
by: Keizer, Ron J., et al.
Published: (2011) -
Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
by: Keizer, Ron J, et al.
Published: (2015) -
Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies
by: Keizer, Ron J., et al.
Published: (2011) -
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
by: Crombag, Marie-Rose B.S., et al.
Published: (2016) -
Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy
by: van Hasselt, J. G. Coen, et al.
Published: (2014)